This site is intended for Healthcare Professionals only

Ustekinumab for adolescents

Latest bookmark icon off

Ustekinumab for adolescents

Ustekinumab (Stelara) is now available for moderate-to-severe plaque psoriasis in patients aged 12 years and older, who are inadequately controlled by, or intolerant of, other systemic therapies or phototherapies.

Plaque psoriasis is a chronic autoimmune disease that is believed to affect 0.5 to two per cent of the general population during childhood and adolescence.

Copy Link copy link button

Latest

Share: